NEW YORK – Bristol Myers Squibb said on Monday that the European Medicines Agency has accepted its marketing authorization application for nivolumab (Opdivo) with chemotherapy as a first-line treatment for patients with advanced or metastatic gastric cancer, gastroesophageal junction cancer, or esophageal adenocarcinoma.